Skip to main content
. 2018 Jul 1;32(13-14):944–952. doi: 10.1101/gad.314658.118

Figure 2.

Figure 2.

Treatment with DPM-1001 improved cell viability in the presence of high levels of copper. (A) Representative immunoblot to demonstrate siRNA-induced suppression of ATP7B in HepG2 cells. (B) Survival of control cells with (▴) or without (•) DPM-1001 and ATP7B-KD1 cells with (gray; ▾) and without (▪) DPM-1001 was measured at increasing concentrations of copper, from 0 to 1.5 mM. Cells were preincubated with DPM-1001 at 2 µM for 1 h prior to exposing cells to copper. (C) Survival of control fibroblasts with (▴) and without (▾) DPM-1001 was compared with fibroblasts derived from Wilson's disease patients (GM00032 [left panel], GM00033 [middle panel], and GM05257 [right panel]) with (gray, •) and without (▪) DPM-1001, measured at increasing concentrations of copper, from 0 to 1.5 mM.